ALBT Avalon GloboCare Corp.
USReal EstateAs of 2026-07-09 12:58
Why ALBT matters now
Avalon GloboCare Corp. (ALBT) is a US stock in Real Estate. The latest InvestLog snapshot shows $0.28 with -3.32% on the session and $1.2M in market capitalization; recent performance reads 1-month +14.48% and YTD -71.67%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-4.5M, and EPS of $-0.50. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -445.0%.
The latest indexable market news headline is "Chief Patrick Flannelly Highlights KetoAir™ Progress in Supporting the Nevada First Responders Holistic Health Reset Program" from GlobeNewsWire.
Additional event context on this page matters because recent insider activity includes Mathews Michael filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.26
P/S
-4.11
EV/EBITDA
-0.12
DCF Value
$-0.11
FCF Yield
-445.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
185.5%
Operating Margin
2903.3%
Net Margin
5579.3%
ROE
-835.0%
ROA
-120.1%
ROIC
-77.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-4.5M | $-0.50 |
| Q4 2025 | $-1.1M | $-1.3M | $-0.44 |
| FY 2025 | $0.00 | $-18.3M | $-5.64 |
| Q3 2025 | $350.1K | $-254.3K | $-0.06 |
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Real Estate
Industry
Real Estate - Services
Country
US
Exchange
—
Beta
-0.05
Avalon GloboCare Corp., along with its affiliated entities, manages and holds commercial real estate assets across both the United States and China. The company's service portfolio encompasses medical consulting, offering diverse solutions such as conducting research studies, delivering executive education, disseminating daily online briefings for executives, providing customized expert advice, and supplying management and consulting expertise, particularly in the fields of immunotherapy and in facilitating second opinions or referrals. Key therapeutic candidates include AVA-001, an anti-CD19 CAR-T therapy, which has successfully completed its initial human clinical trial for B-cell lymphoblastic leukemia that has recurred or is resistant to treatment (R/R). Another promising candidate, AVA-011, also a CAR-T cell therapy, has advanced through preclinical laboratory evaluations and is currently in the IND-enabling process development phase to produce cGMP-grade cells. The company is additionally engaged in the development of an RNA-based FASH-CARTM cell therapy platform. Furthermore, Avalon GloboCare is developing ACTEX, its proprietary clinical-grade, tissue-specific exosome. It collaborates with the Massachusetts Institute of Technology (MIT) to identify therapeutic and diagnostic targets using QTY-code protein design technology, which includes leveraging this technology to create a hemofiltration device for treating Cytokine Storm. The firm also partners with Arbele Limited for the co-development of advanced, transposon-based CAR-T, CAR-NK, and various other multi-target immune effector cell therapies. A strategic alliance with the University of Natural Resources and Life Sciences in Vienna, Austria, aims to develop an S-layer vaccine against SARS-CoV-2 (the virus responsible for COVID-19), designed for intranasal or oral delivery. Beyond these initiatives, the company is progressing with Avalon Cell and Avalon Rehab, and actively advocates for standardization within the exosome industry. Its corporate headquarters are situated in Freehold, New Jersey.